JAN101
Phase 2- Indications
- Peripheral Arterial Disease
Company intelligence / Profile preview
JanOne Inc.
Las Vegas, Nevada, United Statesjanone.com ↗
- Ownership
- Public · JAN
- Development stage
- Phase 2
01
Overview
JanOne’s lead asset, JAN101 (oral sustained-release sodium nitrite), targets poor blood flow and associated pain in diabetic neuropathy and PAD. The company also holds a patent on a novel low-dose naltrexone formulation (JAN123) for chronic pain. Clinical development has reached Phase IIb for PAD; further details on results are not specified in public sources. JanOne recently announced plans to monetize or redeploy its biotech assets as it shifts focus toward fintech following the acquisition of ALT5 Sigma.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecules (e.g., sodium nitrite formulation JAN101)Low-dose naltrexone formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on JanOne Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JanOne Inc..